Sirius Pharma

Sirius Pharma (星锐医药 / Starna Therapeutics) is a Chinese biotech company focused on mRNA drug development. Per a 2022 Source Code Capital piece, it was founded with this specialization and raised a 150 million yuan Series A that May, led by LYFE Capital with Source Code Capital, Hillhouse, Sherpa Healthcare Partners and others participating . The company has since advanced through multiple funding rounds: a Series B of over 300 million yuan in 2025, co-led by LYFE Capital, Hillhouse and LAV, with existing shareholders including Source Code Capital and Sherpa increasing stakes ; and a near-$40 million Series B+ in 2026, again with Source Code Capital doubling down as a continuing backer . The investor lineup across rounds points to sustained conviction from both specialist healthcare funds and major Chinese venture platforms.